[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:small-lymphocytic-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":326},"Small Lymphocytic Lymphoma",102,90,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,96,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,193,199,206,212,218,224,230,236,242,248,254,260,266,272,278,283,289,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06849713","Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL\u002FSLL",[12],"Phase 2","RECRUITING","2026-08-26T02:17:57.997171Z","2026-07-24T01:27:14.890445Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05091424","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia",[20],"Phase 1","2026-08-26T02:18:37.277498Z","2026-07-19T19:36:05.117268Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04269902","Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL\u002FSLL Study",[27],"Phase 3","2026-08-26T02:19:15.498463Z","2026-07-05T05:32:16.774652Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06104566","Global Trial in APG2575 for Patients With CLL\u002FSLL",[27],"2026-08-26T02:18:47.742071Z","2026-07-05T05:32:16.742836Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07221500","A Study of NX-5948 in Adults With CLL\u002FSLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)",[12],"2026-08-26T02:15:24.145250Z","2026-06-17T02:29:30.011779Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07342478","ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R\u002FR CLL\u002FSLL",[27],"2026-08-26T02:18:31.164304Z","2026-05-13T02:55:06.695894Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06333262","Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:29.723824Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06588478","A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:29.588410Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06916767","Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia \u002F Small Lymphocytic Lymphoma",[20],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:29.476288Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05168930","Zanubrutinib and Venetoclax in CLL (ZANU-VEN)",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.060325Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05943496","Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:29.055482Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07014917","Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL\u002FSLL",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.957806Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT04704323","CAP-100 for Subjects With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[20],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:28.873672Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06466122","Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:28.643093Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":101,"content_modified":102},"NCT07052695","Mosunetuzumab for CLL MRD Clearance",[100],"Phase 1\u002FPhase 2","2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.401120Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06978088","LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) and Variants of This",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:28.221100Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT04560322","Venetoclax-Obinutuzumab +\u002F- Acalabrutinib in R\u002FR CLL",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.020733Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT04941716","Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.949857Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06973187","A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[27],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:27.927797Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06136559","A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)\u002F Small Lymphocytic Lymphoma (SLL) (MK-1026-011\u002FBELLWAVE-011)",[27],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.843055Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT07108998","Study of Epcoritamab as a Consolidation Therapy in CLL\u002FSLL",[12],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:27.811784Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06428019","A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)",[27],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:27.678225Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05336812","Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:27.674732Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05947851","A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) (MK-1026-010\u002FBELLWAVE-010).",[27],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:27.628414Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06943872","A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and\u002For Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CELESTIAL-RRCLL)",[27],"2026-08-26T02:19:03.581490Z","2026-05-05T02:43:27.597179Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06757647","Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.399418Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT03516617","Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.295927Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07024706","Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.256129Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05183854","Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial",[12],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:27.167596Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07061951","Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:27.135232Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":204,"content_modified":205},"NCT07218341","A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[203],"Phase 4","2026-08-26T02:16:09.452956Z","2026-05-05T02:43:27.102864Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT05254743","A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[27],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:26.921381Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT06846671","A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia\u002FLymphoma 2 Protein (BCL2) Inhibitors",[27],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.916641Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT07194980","Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[12],"2026-08-26T02:15:39.267524Z","2026-05-05T02:35:31.915439Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT06520098","A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:35:31.911839Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT07218510","Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:35:31.644407Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT04215809","Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL\u002FSLL",[20],"2026-08-26T02:15:00.557154Z","2026-04-29T02:57:57.127455Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT06863402","Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype",[12],"2026-08-26T02:15:54.846520Z","2026-07-24T01:27:14.890802Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[100],"2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT06839053","Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:28.514202Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL",[100],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.285448Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.592999Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":276,"content_modified":277},"NCT05388006","Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.040607Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":119,"content_modified":282},"NCT06351527","Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies",[20],"2026-04-29T02:57:57.106080Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[100],"2026-08-26T02:18:40.612983Z","2026-07-30T01:46:14.462113Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":46,"content_modified":293},"NCT07572006","A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies",[20],"2026-07-24T01:27:14.897977Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT05006716","A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies",[100],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.799692Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[20],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":143,"content_modified":310},"NCT06564038","A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",[100],"2026-05-05T02:43:29.532592Z",[312,316,320,323],{"biomarker":313,"count":314,"slug":315},"CD19 Gene",7,"cd19-gene",{"biomarker":317,"count":318,"slug":319},"BCR\u002FABL1 Fusion Gene",3,"bcr-abl1-fusion-gene",{"biomarker":321,"count":318,"slug":322},"BTK Gene","btk-gene",{"biomarker":324,"count":318,"slug":325},"MS4A1 Gene","ms4a1-gene",[327,331,335,339,343,347,351,355,359,363,367,371,374,378,382,386,389,392,395,398,401,405,409,413],{"state":328,"count":329,"slug":330},"Texas",41,"texas",{"state":332,"count":333,"slug":334},"Ohio",38,"ohio",{"state":336,"count":337,"slug":338},"California",35,"california",{"state":340,"count":341,"slug":342},"North Carolina",32,"north-carolina",{"state":344,"count":345,"slug":346},"Florida",31,"florida",{"state":348,"count":349,"slug":350},"New York",27,"new-york",{"state":352,"count":353,"slug":354},"Washington",24,"washington",{"state":356,"count":357,"slug":358},"Massachusetts",23,"massachusetts",{"state":360,"count":361,"slug":362},"Minnesota",20,"minnesota",{"state":364,"count":365,"slug":366},"Maryland",18,"maryland",{"state":368,"count":369,"slug":370},"Colorado",17,"colorado",{"state":372,"count":369,"slug":373},"Michigan","michigan",{"state":375,"count":376,"slug":377},"Pennsylvania",16,"pennsylvania",{"state":379,"count":380,"slug":381},"Illinois",15,"illinois",{"state":383,"count":384,"slug":385},"Arizona",14,"arizona",{"state":387,"count":384,"slug":388},"Oregon","oregon",{"state":390,"count":384,"slug":391},"Tennessee","tennessee",{"state":393,"count":384,"slug":394},"Utah","utah",{"state":396,"count":384,"slug":397},"Virginia","virginia",{"state":399,"count":384,"slug":400},"Wisconsin","wisconsin",{"state":402,"count":403,"slug":404},"New Jersey",13,"new-jersey",{"state":406,"count":407,"slug":408},"Missouri",12,"missouri",{"state":410,"count":411,"slug":412},"Georgia",10,"georgia",{"state":414,"count":411,"slug":415},"Indiana","indiana"]